Research: 2000–2009
🐀 = animal study 🧬 = genetics focus 📚 = systematic review / meta-analysis
All periods: 2020–present | 2015–2019 | 2010–2014 | 2000–2009 | 1942–1999
Jump to: 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000
2009
Anitha B, Inamadar AC, Ragunatha S. Finasteride-its impact on sexual function and prostate cancer. J Cutan Aesthet Surg. 2009;2(1):12-16. doi:10.4103/0974-2077.53093. Journal site • PubMed
Christiansen S, Scholze M, Dalgaard M, et al. Synergistic disruption of external male sex organ development by a mixture of four antiandrogens. Environ Health Perspect. 2009 Dec. doi:10.1289/ehp.0900689 • PubMed • PMC full text
Do C, Huyghe E, Lapeyre-Mestre M, Montastruc JL, Bagheri H. Statins and erectile dysfunction: results of a case/non-case study using the French Pharmacovigilance System Database. Drug Saf. 2009. doi:10.2165/00002018-200932070-00005 • PubMed
🐀🧬 Duarte-Guterman P, Langlois VS, Hodgkinson K, et al. The aromatase inhibitor fadrozole and the 5-reductase inhibitor finasteride affect gonadal differentiation and gene expression in the frog Silurana tropicalis. Sex Dev. 2009. doi:10.1159/000280586 • PubMed
Dusková M, Hill M, Hanus M, Matousková M, Stárka L. Finasteride treatment and neuroactive steroid formation. Prague Med Rep. 2009. Journal site • PubMed
🐀 Kolasa A, Marchlewicz M, Kurzawa R, et al. The expression of inducible nitric oxide synthase (iNOS) in the testis and epididymis of rats with a dihydrotestosterone (DHT) deficiency. Cell Mol Biol Lett. 2009. doi:10.2478/s11658-009-0019-z • PubMed • PMC full text
Mansouri P, Farshi S, Safar F. Finasteride-induced gynecomastia. Indian J Dermatol Venereol Leprol. 2009. doi:10.4103/0378-6323.51273 • PubMed
Ramot Y, Czarnowicki T, Zlotogorski A. Finasteride induced gynecomastia: case report and review of the literature. Int J Trichology. 2009. doi:10.4103/0974-7753.51930 • PubMed
Sallout BI, Al Wadi KA. Aphalangia possibly linked to unintended use of finasteride during early pregnancy. Ann Saudi Med. 2009. doi:10.4103/0256-4947.51805 • PubMed • PMC full text
🐀 Serga, CNK. The effect of different doses of finasteride on sperm morphology and motility and reactive oxygen species concentrations in rats. Med J Cairo Univ. 2009. Journal site • PDF on semanticscholar.org
Smith AB, Carson CC. Finasteride in the treatment of patients with benign prostatic hyperplasia: a review. Ther Clin Risk Manag. 2009;5(3):535–545. doi:10.2147/tcrm.s6195 • PubMed
🐀 Urbatzka R, Watermann B, Lutz I, Kloas W. Exposure of Xenopus laevis tadpoles to finasteride, an inhibitor of 5-alpha reductase activity, impairs spermatogenesis and alters hypophyseal feedback mechanisms. J Mol Endocrinol. 2009. doi:10.1677/JME-09-0058 • PubMed • Free access
🐀 Yawno T, Hirst JJ, Castillo-Melendez M, Walker DW. Role of neurosteroids in regulating cell death and proliferation in the late gestation fetal brain. Neuroscience. 2009. doi:10.1016/j.neuroscience.2009.07.009 • PubMed
2008
Al-Harbi TM, Kagan J, Tarnopolsky MA. Finasteride-induced myalgia and HyperCKemia. J Clin Neuromuscul Dis. 2008 Dec;10(2):76-8. doi:10.1097/CND.0b013e3181873cca | PubMed
[⚠️ Funded by GlaxoSmithKline] Amory JK, Anawalt BD, Matsumoto AM, et al. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men. J Urol. 2008;179(6):2333-2338. doi:10.1016/j.juro.2008.01.145 | PubMed
Erdemir F, Harbin A, Hellstrom WJ. 5-alpha reductase inhibitors and erectile dysfunction: the connection. J Sex Med. 2008;5(12):2917-2924. doi:10.1111/j.1743-6109.2008.01001.x | PubMed
Gur S, Kadowitz PJ, Hellstrom WJ. Guide to drug therapy for lower urinary tract symptoms in patients with benign prostatic obstruction : implications for sexual dysfunction. Drugs. 2008;68(2):209-29. doi:10.2165/00003495-200868020-00005 | PubMed
Hamdy FC, Rouprêt M. [The PCPT trial]. Prog Urol. 2008;18 Suppl 3:S40-3. doi:10.1016/S1166-7087(08)70512-8
🐀 Kolasa A, Marchlewicz M, Adler G, Ciechanowicz A, Głabowski W, Wiszniewska B. Expression of E-SOD, GPX5 mRNAs and immunoexpression of Cu/ZnSOD in epididymal epithelial cells of finasteride-treated rats. Andrologia. 2008 Oct;40(5):303-11. doi:10.1111/j.1439-0272.2008.00858.x | PubMed
Liu KE, Binsaleh S, Lo KC, Jarvi K. Propecia-induced spermatogenic failure: a report of two cases. Fertil Steril. 2008;90(3):. doi:10.1016/j.fertnstert.2007.08.026 | PubMed
Lombardo, R., Loraschi, A., Lecchini, S. et al. Finasteride-Associated Central Serious Chorioretinopathy. Drug Safety. 2008;31:885. doi:10.2165/00002018-200831100-00098
🐀 Martín-García E, Darbra S, Pallarés M. Neonatal finasteride induces anxiogenic-like profile and deteriorates passive avoidance in adulthood after intrahippocampal neurosteroid administration. Neuroscience. 2008;154(4):1497-1505. doi:10.1016/j.neuroscience.2008.04.062 | PubMed
🐀 Parivar K, Yaghmaei P, Sekhavati S. The role and effect of finasteride on the spermatogenesis, prostate gland and epididym of mature NMRI mouse in in vivo and in vitro conditions. Med Sci J Islam Azad Univ. 2008;179:2333-8. PDF at iautmu.ac.ir
Sarvis JA, Thompson IM. Prostate cancer chemoprevention: update of the prostate cancer prevention trial findings and implications for clinical practice. Curr Oncol Rep. 2008;10(6):529-532. doi:10.1007/s11912-008-0080-1 | PubMed
Wilt TJ, MacDonald R, Hagerty K, Schellhammer P, Kramer BS. Five-alpha-reductase Inhibitors for prostate cancer prevention. Cochrane Database Syst Rev. 2008;(2):CD007091. doi:10.1002/14651858.CD007091
2007
Al Hammadi A, Asai Y, Patt ML, Sasseville D. Erythema annulare centrifugum secondary to treatment with finasteride. J Drugs Dermatol. 2007;6(4):460-463. PubMed
[⚠️ Funded by GlaxoSmithKline] Amory JK, Wang C, Swerdloff RS, et al. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men [published correction appears in J Clin Endocrinol Metab. 2007 Nov;92(11):4379]. J Clin Endocrinol Metab. 2007;92(5):1659–1665. doi:10.1210/jc.2006-2203 | PubMed
Atrian H, Khatamsaz S, Mokhtari M. Evaluating histological modifications of testis and spermatogenesis in adult male rats on finasteride. Journal of Reproduction & Infertility. 2007;8(2):122–127. Journal site
Collodel G, Scapigliati G, Moretti E. Spermatozoa and chronic treatment with finasteride: a TEM and FISH study. Arch Androl. 2007 Jul-Aug;53(4):229-33. doi:10.1080/01485010701426471 | PubMed
Fernández Olarte D, Morán García A, Iglesias Bonilla P, Ortega Calvo M. Ginecomastia por dutasterida [Dutasteride-induced gynecomastia]. Med Clin (Barc). 2007 Feb 24;128(7):279. Spanish. doi:10.1016/s0025-7753(07)72563-0 | PubMed
Issa SA, Dagres E. Intraoperative floppy iris syndrome and finasteride intake. J Cataract Refect Surg. 2007;33:2142–2143. doi:10.1016/j.jcrs.2007.07.025 | PubMed
Moinpour CM, Darke AK, Donaldson GW, et al. Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007;99(13):1025–1035. doi:10.1093/jnci/djm023 | PubMed
Mondaini N, Gontero P, Giubilei G, et al. Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon? J Sex Med. 2007;4(6):1708-1712. doi:10.1111/j.1743-6109.2007.00563.x | PubMed
Naslund MJ, Miner M. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate. Clin Ther. 2007;29(1):17-25. doi:10.1016/j.clinthera.2007.01.018 | PubMed
🐀 Wu YG, Li SK, Xin ZC, et al. [The establishment of hypospadias rat model and embryoteratogenic test of Atrazine]. Zhonghua Zheng Xing Wai Ke Za Zhi. 2007 Jul;23(4):340-3. Chinese. PubMed
Yeu E, Grostern R. Saw palmetto and intraoperative floppy-iris syndrome. J Cataract Refract Surg. 2007 May;33(5):927-8. doi:10.1016/j.jcrs.2006.12.032 | PubMed
2006
🐀 de Brito Faturi C, Teixeira-Silva F, Leite JR. The anxiolytic effect of pregnancy in rats is reversed by finasteride. Pharmacol Biochem Behav. 2006;85(3):569-574. doi:10.1016/j.pbb.2006.10.011 | PubMed
Carson CC. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both? BJU Int. 2006;97 Suppl 2:39-43; discussion 44-5. doi:10.1111/j.1464-410X.2006.06105.x
Finn DA, Beadles-Bohling AS, Beckley EH, et al. A new look at the 5alpha-reductase inhibitor finasteride. CNS Drug Rev. 2006;12(1):53-76. doi:10.1111/j.1527-3458.2006.00053.x
Giuliano F. Impact of medical treatments for benign prostatic hyperplasia on sexual function. BJU Int. 2006;97 Suppl 2:34-38; discussion 44-5. doi:10.1111/j.1464-410X.2006.06104.x
Kawashima M, Mizoguchi M, Igarashi A. Long term (3 years) efficacy and safety profiles of finasteride in Japanese men with AGA (androgenetic alopecia). Jpn J Clin Dermatol. 2006;60:521-530. CiNii record
🐀 Mann PE. Finasteride delays the onset of maternal behavior in primigravid rats. Physiol Behav. 2006;88(4-5):333-338. doi:10.1016/j.physbeh.2006.04.008 | PubMed
Martínez de Guzmán M, Martínez-Crespo JJ. Hepatitis por finasterida [Finasteride-induced hepatitis]. Farm Hosp. 2006 Nov-Dec;30(6):385. Spanish. doi:10.1016/s1130-6343(06)74011-9 | PubMed
Miner M, Rosenberg MT, Perelman MA. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function. Clin Ther. 2006;28(1):13-25. doi:10.1016/j.clinthera.2006.01.004
Rahimi-Ardabili B, Pourandarjani R, Habibollahi P, Mualeki A. Finasteride induced depression: a prospective study. BMC Clin Pharmacol. 2006;6:7. doi:10.1186/1472-6904-6-7 | PubMed
🐀 Robaire B, Henderson NA. Actions of 5alpha-reductase inhibitors on the epididymis. Mol Cell Endocrinol. 2006;250(1-2):190–195. doi:10.1016/j.mce.2005.12.044 | PubMed
Ryu HK, Kim KM, Yoo EA, Sim WY, Chung BC. Evaluation of androgens in the scalp hair and plasma of patients with male-pattern baldness before and after finasteride administration. Br J Dermatol. 2006;154(4):730‐734. doi:10.1111/j.1365-2133.2005.07072.x | PubMed
2005
Djavan B, Milani S, Fong YK. Dutasteride: a novel dual inhibitor of 5alpha-reductase for benign prostatic hyperplasia. Expert Opin Pharmacother. 2005;6(2):311-317. doi:10.1517/14656566.6.2.311
🐀 Henderson NA, Robaire B. Effects of PNU157706, a dual 5alpha-reductase inhibitor, on rat epididymal sperm maturation and fertility. Biol Reprod. 2005 Feb;72(2):436-43. doi:10.1095/biolreprod.104.033548 | PubMed
🐀 Jia Y, Cue YG, Wang XD, Wang XH, Tong JS, Ma DZ, Cai RF, Di FS. [Effect of selective 5alpha-reductase inhibitor or/and testosterone undecanoate on the reproductive function of male rats]. Zhonghua Nan Ke Xue. 2005 Jan;11(1):38-41. Chinese. PubMed
Kaya C, Ozyurek M, Turkeri LN. Comparison of microvessel densities in rat prostate tissues treated with finasteride, bicalutamide and surgical castration: a preliminary study. Int J Urol. 2005 Feb;12(2):194-8. doi:10.1111/j.1442-2042.2005.01005.x | PubMed
Kuritzky L. Noninvasive management of lower urinary tract symptoms and sexual dysfunction associated with benign prostatic hyperplasia in the primary care setting. Compr Ther. 2005;31(3):194-208. doi:10.1385/comp:31:3:194
[⚠️ Supported by Merck; two co-authors were Merck employees] Leavitt M, Perez-Meza D, Rao NA, Barusco M, Kaufman KD, Ziering C. Effects of finasteride (1 mg) on hair transplant. Dermatol Surg. 2005 Oct;31(10):1268-76, discussion 1276. doi:10.1111/j.1524-4725.2005.31202 • PubMed
Marihart S, Harik M, Djavan B. Dutasteride: a review of current data on a novel dual inhibitor of 5alpha reductase. Rev Urol. 2005;7(4):203-210. PubMed
McVary KT. Sexual Function and α-Blockers. Rev Urol. 2005;7(Suppl 8):S3-S11. PubMed
[⚠️ Includes Merck researcher(s)] Paick SH, Meehan A, Lee M, Penson DF, Wessells H. The relationship among lower urinary tract symptoms, prostate specific antigen and erectile dysfunction in men with benign prostatic hyperplasia: results from the proscar long-term efficacy and safety study. J Urol. 2005;173(3):903-907. doi:10.1097/01.ju.0000152088.00361.a7 | PubMed
🐀 Ribeiro CM, Pereira OC. 5alpha-reductase 2 inhibition impairs brain defeminization of male rats: reproductive aspects. Pharmacol Biochem Behav. 2005;82(1):228-235. doi:10.1016/j.pbb.2005.08.015 | PubMed
Rosen RC, Giuliano F, Carson CC. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol. 2005;47(6):824–837. doi:10.1016/j.eururo.2004.12.013 | PubMed
🐀 Shen ZJ, Chen SW, Lu YL, et al. Preliminary study on androgen dependence of calcitonin gene-related peptide in rat penis. Asian J Androl. 2005 Mar;7(1):55-9. doi:10.1111/j.1745-7262.2005.00003.x | PubMed
📚 Thomson A. Dutasteride: an evidence-based review of its clinical impact in the treatment of benign prostatic hyperplasia. Core Evid. 2005;1(2):143-156. PubMed
🧬 Wakisaka N, Taira Y, Ishikawa M, et al. Effectiveness of finasteride on patients with male pattern baldness who have different androgen receptor gene polymorphism. J Investig Dermatol Symp Proc. 2005;10(3):293-294. doi:10.1111/j.0022-202X.2005.10123.x | PubMed
Wang XD, Jia Y, Cui YG, Wang XH, Tong JS, Ma DZ, Cai RF, Di FS. [Effect of large-dosage of 5alpha-reductase inhibitors on the spermatogenesis of male rats]. Zhonghua Nan Ke Xue. 2005 Sep;11(9):652-4. Chinese. PubMed
2004
Chou SY, Kao SC, Hsu WM. Propecia-associated bilateral cataract. Clin Exp Ophthalmol. 2004 Feb;32(1):106-8. doi:10.1046/j.1442-9071.2004.00770.x | PubMed
Glina S, Neves PA, Saade R, Netto NR Jr, Soares JB, Galuppo AG. Finasteride-associated male infertility. Rev Hosp Clin Fac Med Sao Paulo. 2004 Aug;59(4):203-5. doi:10.1590/s0041-87812004000400009 | PubMed
Klein EA, Thompson IM. Update on chemoprevention of prostate cancer. Curr Opin Urol. 2004;14(3):143-149. doi:10.1097/00042307-200405000-00002 | PubMed
Lechuga Sancho AM, Hernández Serrano R, González Casado I, Gracia Bouthelier R. Recién nacido con extrofia vesical y posible exposición intrauterina a finasterida [Newborn with bladder extrophy associated with finasteride exposure]. An Pediatr (Barc). 2004 Nov;61(5):451-3. doi:10.1016/s1695-4033(04)78429-5 | PubMed | Unofficial translation
Lee SC, Ellis RJ. Male breast cancer during finasteride therapy. J Natl Cancer Inst. 2004. doi:10.1093/jnci/djh062 • PubMed
Libecco JF, Bergfeld WF. Finasteride in the treatment of alopecia. Expert Opin Pharmacother. 2004 Apr;5(4):933-40. doi:10.1517/14656566.5.4.933 | PubMed
🐀 🧬 Liu XD, Li H, Bu H, et al. [Effects of finasteride on capillary in the ventral prostate of rat]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2004 Mar;35(2):226-8. Chinese. PubMed
Marks LS. 5alpha-reductase: history and clinical importance. Rev Urol. 2004;6 Suppl 9(Suppl 9):S11-21. PubMed
Pitts WR Jr. Finasteride (Propecia) and the promotion of high-grade prostate cancer. Arch Dermatol. 2004;140(7):885‐886. doi:10.1001/archderm.140.7.885-b | PubMed
Schmutz JL, Barbaud A, Trechot P. Gynécomastie et finastéride (Propecia): 4 nouveaux cas [Gynecomastia and finasteride (Propecia): 4 new cases]. Ann Dermatol Venereol. 2004 Jun-Jul;131(6-7 Pt 1):615. French. doi:10.1016/s0151-9638(04)93684-8 | PubMed
Tosti A, Pazzaglia M, Soli M, et al. Evaluation of sexual function with an international index of erectile function in subjects taking finasteride for androgenetic alopecia. Arch Dermatol. 2004;140(7):857-858. doi:10.1001/archderm.140.7.857 | PubMed
[Comment] Seftel A. Evaluation of sexual function with an international index of erectile function in subjects taking finasteride for androgenetic alopecia. J Urol. 2005. doi:10.1016/S0022-5347(05)60540-X
Townsend KA, Marlowe KF. Relative safety and efficacy of finasteride for treatment of hirsutism. Ann Pharmacother. 2004 Jun;38(6):1070-3. doi:10.1345/aph.1D461 | PubMed
Zaballos P, Rodero J, Vives JM, Magarolas A, Andreu M. [Unilateral gynecomastia secondary to treatment with finasteride]. Actas Dermo-Sifiliograficas. 2004 Apr;95(3):199-200. Spanish. Journal site
2003
Altomare G, Capella GL. Depression circumstantially related to the administration of finasteride for androgenetic alopecia. J Dermatol. 2002;29(10):665–669. doi:10.1111/j.1346-8138.2002.tb00200.x | PubMed
[Comment] Pope JE, Makela EH. Response to article “Depression circumstantially related to the administration of finasteride for androgenetic alopecia” (J Dermatol, 29, 665-669, 2002). J Dermatol. 2003;30(11):837–844. doi:10.1111/j.1346-8138.2003.tb00488.x | PubMed
🐀 Bowman CJ, Barlow NJ, Turner KJ, Wallace DG, Foster PM. Effects of in utero exposure to finasteride on androgen-dependent reproductive development in the male rat. Toxicol Sci. 2003;74(2):393-406. doi:10.1093/toxsci/kfg128 | PubMed
Carbone DJ, Hodges S. Medical therapy for benign prostatic hyperplasia: sexual dysfunction and impact on quality of life. Int J Impot Res. 2003;15(4):299-306. doi:10.1038/sj.ijir.3901017
Kassabian VS. Sexual function in patients treated for benign prostatic hyperplasia. Lancet. 2003;361(9351):60-62. doi:10.1016/S0140-6736(03)12164-2 | PubMed
Larson TR. Current treatment options for benign prostatic hyperplasia and their impact on sexual function. Urology. 2003;61(4):692-698. doi:10.1016/s0090-4295(02)02552-9
Lowe FC, McConnell JD, Hudson PB, et al. Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology. 2003;61(4):791-796. doi:10.1016/s0090-4295(02)02548-7
McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387–2398. doi:10.1056/NEJMoa030656 | PubMed
Pareek G, Shevchuk M, Armenakas NA, Vasovic L, Hochberg DA, Basillote JB, Fracchia JA. The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients. J Urol. 2003 Jan;169(1):20-3. doi:10.1097/01.ju.0000039923.75777.91 | PubMed
Roehrborn CG, Lee M, Meehan A, Waldstreicher J, Group PS. Effects of finasteride on serum testosterone and body mass index in men with benign prostatic hyperplasia. Urology. 2003;62(5):894-899. doi:10.1016/s0090-4295(03)00661-7
Sadeghi-Nejad H, Sherman N, Lue J. Comparison of finasteride and alpha-blockers as independent risk factors for erectile dysfunction. Int J Clin Pract. 2003;57(6):484-487. PubMed
[⚠️ Authored by a consultant to Merck and head of Propecia development at Merck] Shapiro J, Kaufman KD. Use of finasteride in the treatment of men with androgenetic alopecia (male pattern hair loss). J Investig Dermatol Symp Proc. 2003. doi:10.1046/j.1523-1747.2003.12167.x • PubMed
🐀 Shen ZJ, Zhou XL, Lu YL, Chen ZD. Effect of androgen deprivation on penile ultrastructure. Asian J Androl. 2003 Mar;5(1):33-6. Abstract (archive.org) | Full text (archive.org) | PubMed
Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215-224. doi:10.1056/NEJMoa030660 | PubMed
Thompson IM, Klein EA, Lippman SM, Coltman CA, Djavan B. Prevention of prostate cancer with finasteride: US/European perspective. Eur Urol. 2003;44(6):650-655. doi:10.1016/j.eururo.2003.11.001
[⚠️ Sponsored by Merck] Wessells H, Roy J, Bannow J, et al. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology. 2003;61(3):579-584. doi:10.1016/s0090-4295(02)02401-9
Whiting DA, Olsen EA, Savin R, et al. Efficacy and tolerability of finasteride 1 mg in men aged 41 to 60 years with male pattern hair loss. Eur J Dermatol. 2003;13(2):150-160. PubMed
2002
📚 Edwards JE, Moore RA. Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials. BMC Urol. 2002;2:14. doi:10.1186/1471-2490-2-14
Ferrando J, Grimalt R, Alsina M, Bulla F, Manasievska E. Unilateral gynecomastia induced by treatment with 1 mg of oral finasteride. Arch Dermatol. 2002;138(4):543‐544. doi:10.1001/archderm.138.4.543 | PubMed
Finasteride Male Pattern Hair Loss Study Group. Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Eur J Dermatol. 2002 Jan-Feb;12(1):38-49. PubMed
Häggström S, Tørring N, Møller K, et al. Effects of finasteride on vascular endothelial growth factor. Scand J Urol Nephrol. 2002. DOI • PubMed
🐀 Huynh H. Induction of apoptosis in rat ventral prostate by finasteride is associated with alteration in MAP kinase pathways and Bcl-2 related family of proteins. Int J Oncol. 2002;20(6):1297-1303. PubMed
Kouriefs C, Betambeau N, Rowbotham C, Coyne K, Rowley M, Jones CR. Finasteride-induced thrombocytopenia. BJU Int. 2002 Aug;90(3):348-9. doi:10.1046/j.1464-410x.2002.02851.x • PubMed
Leliefeld HH, Stoevelaar HJ, McDonnell J. Sexual function before and after various treatments for symptomatic benign prostatic hyperplasia. BJU Int. 2002;89(3):208-213. doi:10.1046/j.1464-4096.2001.01817.x
[⚠️ Funded by Merck] Matsumoto AM, Tenover L, McClung M, et al; PLESS Study Group. The long-term effect of specific type II 5alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial. J Urol. 2002 May;167(5):2105-8. PubMed
[⚠️ Funded by Merck] Price VH, Menefee E, Sanchez M, Ruane P, Kaufman KD. Changes in hair weight and hair count in men with androgenetic alopecia after treatment with finasteride, 1 mg, daily. J Am Acad Dermatol. 2002;46(4):517–523. doi:10.1067/mjd.2002.120537 | PubMed
🐀 Rhoden EL, Gobbi D, Menti E, Rhoden C, Telöken C. Effects of the chronic use of finasteride on testicular weight and spermatogenesis in Wistar rats. BJU Int. 2002 Jun;89(9):961-3. doi:10.1046/j.1464-410x.2002.02785.x | PubMed
[⚠️ Funded by Yamanouchi Europe] Souverein PC, Herings RM, Man in ‘t Veld AJ, de la Rosette JJ, Farmer RD, Leufkens HG. Study of the association between ischemic heart disease and use of alpha-blockers and finasteride indicated for the treatment of benign prostatic hyperplasia. Eur Urol. 2002 Sep. doi:10.1016/s0302-2838(02)00273-7 • PubMed
[⚠️ Includes Merck researchers] Stough DB, Rao NA, Kaufman KD, Mitchell C. Finasteride improves male pattern hair loss in a randomized study in identical twins. Eur J Dermatol. 2002 Jan-Feb;12(1):32-7. PubMed
2001
🐀 Dadras SS, Cai X, Abasolo I, Wang Z. Inhibition of 5alpha-reductase in rat prostate reveals differential regulation of androgen-response gene expression by testosterone and dihydrotestosterone. Gene Expr. 2001;9(4-5):183–194. doi:10.3727/000000001783992551 | PubMed | PMC full text
[Possibly withdrawn; journal did not know article status] Frye CA. Inhibition of 5alpha-reductase enzyme or GABA(A) receptors in the VMH and the VTA attenuates progesterone-induced sexual behavior in rats and hamsters. J Endocrinol Invest. 2001 Jun;24(6):399-407. Journal issue [article does not appear in table of contents] • PubMed
Harth W, Linse R. Body dysmorphic disorder and life-style drugs. Overview and case report with finasteride. Int J Clin Pharmacol Ther. 2001 Jul;39(7):284-7. doi:10.5414/cpp39284 | PubMed
Kaplan SA. 5alpha-reductase inhibitors: what role should they play?. Urology. 2001;58(6 Suppl 1):65–70. doi:10.1016/s0090-4295(01)01347-4 | PubMed
Kaplan SA, Holtgrewe HL, Bruskewitz R, et al. Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia. Urology. 2001;57(6):1073–1077. doi:10.1016/s0090-4295(01)00985-2 | PubMed
Lange K, Cordes EK, Hoppen HO, Günzel-Apel AR. Determination of concentrations of sex steroids in blood plasma and semen of male dogs treated with delmadinone acetate or finasteride. J Reprod Fertil Suppl. 2001;57:83-91. PubMed
O’Leary MP. Quality of life and sexuality: methodological aspects. Eur Urol. 2001;40 Suppl 3:13-18. doi:10.1159/000049886
Pole M, Koren G. Finasteride. Does it affect spermatogenesis and pregnancy?. Can Fam Physician. 2001;47:2469–2470. PMC full text | PubMed
Schulman C. Impact of treatment of BPH on sexuality. Prostate Cancer Prostatic Dis. 2001;4(S1):S12-S16. doi:10.1038/sj.pcan.4500541
Sinclair RD. Management of male pattern hair loss. Cutis. 2001 Jul;68(1):35-40. Journal site | PubMed
Stoevelaar HJ, McDonnell J. Changing therapeutic regimens in benign prostatic hyperplasia. Clinical and economic considerations. Pharmacoeconomics. 2001;19(2):131-153. doi:10.2165/00019053-200119020-00003 | PubMed
Tosti A, Piraccini BM, Soli M. Evaluation of sexual function in subjects taking finasteride for the treatment of androgenetic alopecia. J Eur Acad Dermatol Venereol. 2001;15(5):418-421. doi:10.1046/j.1468-3083.2001.00315.x | PubMed
Whiting DA. Advances in the treatment of male androgenetic alopecia: a brief review of finasteride studies. Eur J Dermatol. 2001 Jul-Aug;11(4):332-4. PubMed
Wise GJ, Md EO. Hormonal treatment of patients with benign prostatic hyperplasia: pros and cons. Curr Urol Rep. 2001;2(4):285-291. doi:10.1007/s11934-001-0065-1
2000
Clifford GM, Farmer RD. Medical therapy for benign prostatic hyperplasia: a review of the literature. Eur Urol. 2000;38(1):2-19. doi:10.1159/000020246
Krenzer KL, Dana MR, Ullman MD, Cermak JM, Tolls DB, Evans JE, Sullivan DA. Effect of androgen deficiency on the human meibomian gland and ocular surface. J Clin Endocrinol Metab. 2000 Dec;85(12):4874-82. doi:10.1210/jcem.85.12.7072 | PubMed
🐀 Kurzrock EA, Jegatheesan P, Cunha GR, Baskin LS. Urethral development in the fetal rabbit and induction of hypospadias: a model for human development. J Urol. 2000 Nov;164(5):1786-92. PubMed
Van Neste D, Fuh V, Sanchez-Pedreno P, et al. Finasteride increases anagen hair in men with androgenetic alopecia. Br J Dermatol. 2000;143(4):804-810. doi:10.1046/j.1365-2133.2000.03780.x | PubMed
Wade MS, Sinclair RD. Reversible painful gynaecomastia induced by low dose finasteride (1 mg/day). Australas J Dermatol. 2000 Feb;41(1):55. doi:10.1046/j.1440-0960.2000.00392.x | PubMed
Zimmerman RL, Fogt F, Cronin D, Lynch R. Cytologic atypia in a 53-year-old man with finasteride-induced gynecomastia. Arch Pathol Lab Med. 2000;124(4):625-7. doi:10.5858/2000-124-0625-CAIAYO • PubMed
Bibliographies: 2020–present | 2015–2019 | 2010–2014 | 2000–2009 | 1942–1999